By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
On March 22, 2023, the U.S. Food and Drug Administration granted accelerated approval to retifanlimab-dlwr — a humanized monoclonal antibody that targets human PD-1 — for adult patients with metastatic or recurrent
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary refractory Large b-cell lymphoma who were candidates
By Dr. Radhika Kulkarni Henry Ford Cancer Institute On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published in the New England Journal of Medicine. This
